Healthcare / BiotechnologyShanghai
$56.09
-1.61 (-2.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-133.1M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-8.7%
↓Gross Margin
17.4%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.2%
FCF CAGR
—
FCF margin
3.1%
FCF / Net income
-0.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.16B · net income $-167.8M · FCF $36.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.16B | $1.16B | $1.04B | $1.37B | $1.66B |
| Net Income | $-167.8M | $-167.8M | $-330.8M | $-33.2M | $338.2M |
| EBITDA | $-65.0M | $-65.0M | $-261.4M | $54.2M | $452.2M |
| EPS | -1.27 | -1.27 | -2.47 | -0.26 | 2.78 |
| Gross Margin | 17.4% | 17.4% | 6.3% | 23.8% | 40.8% |
| Operating Margin | -8.4% | -8.4% | -20.9% | 0.4% | 23.0% |
| Net Margin | -14.4% | -14.4% | -31.9% | -2.4% | 20.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.16 | 0.15 | 0.17 |
| Current Ratio | 1.93 | 1.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $36.1M | $36.1M | $-133.1M | $-152.4M | $-425.4M |
| Returns | |||||
| ROE | -8.7% | -8.7% | -15.5% | -1.3% | 21.1% |
| Valuation | |||||
| P/E | — | — | — | — | 58.60 |
| EV/EBITDA | — | — | — | 151.69 | 44.01 |
| P/B | 3.83 | 3.83 | 1.76 | 3.31 | 12.37 |
| Growth & Yield | |||||
| Revenue Growth | 12.1% | 12.1% | -24.0% | -17.7% | — |
| EPS Growth | 48.6% | 48.6% | -850.0% | -109.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+79.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.47 → -1.27
Residual
+79.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.